References
- Sauer M V. Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy. Reprod Biomed Online 2006; 12: 153–162
- Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri P N. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod 2006; 21: 2121–2125
- Lindheim S R, Morales J. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003; 18: 2048–2051
- Ricciarelli E, Sanchez M, Martínez M, Andrés L, Cuadros J, Hernandez E. Impact of the gonadotropin-releasing hormone antagonist in oocyte donation cycles. Fertil Steril 2003; 79: 1461–1463
- Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vandezwalmen P, Schoysman R, Makedos G. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 2005; 20: 1516–1520
- Fauser B C, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren H G. Endocrine profiles after triggering of final oocyte maturation with GnRH after cotreatment with GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709–716
- Kolibianakis E M, Collins J, Tarlatzis B, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of GnRH-analogue used? A systematic review and meta-analysis. Hum Reprod 2006; 12: 651–671
- Al-Inany H, AbouSetta A, Mansour R, Serour G, Aboulghar M. GnRH agonist vs. antagonist in assisted reproduction: a Cochrane review. Reprod Biomed Online 2007; 14: 640–649
- Plachot M, Mandelbaum J, Junca A. Qualité de l'oocyte et de l'embryon et résultat de la FIV. Contracept Fertil Sex 1990; 18: 636–638
- Weiss N. Gonadotrophin products: empowering patients to chose the product that meets their needs. Reprod Biomed Online 2007; 1: 31–37
- Van Wely M, Westergaard L G, Bossuyt P M, Van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003; 80: 1086–1093
- Platteau P, Laurenti E, Albano C. An open, randomized single-centre study to compare the efficacy and convenience of follitropin β administered by a pen device with follitropin α administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2003; 18: 1200–1204
- Andersen A N, Devroey P, Arce JC for the MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006; 21: 3217–3227
- Bodri D, Vernaeve V, Guillén J J, Vidal R, Figueras F, Coll O. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod 2006; 21: 2246–2251